A single bout of resistance or high-intensity interval training increases anti-cancer myokines and suppresses cancer cell growth in vitro in survivors of breast cancer.
Breast cancer research and treatment · 2026
One exercise session nudges anti-cancer myokines and dents cancer cells in a dish, but that is biology, not a recurrence-risk result.
What they found
Decorin, IL-6 and SPARC rose 9-47% immediately post-exercise in both groups (p<0.05), IL-6 stayed elevated at 30 min, and OSM rose only in the RT group at 30 min; MDA-MB-231 cell growth fell 19-29% at 0 and 30 min in both groups (p<0.05), with HIIT producing a significantly larger drop than RT at 0 min (p=0.001).
Study design
Parallel-group randomised controlled trial, acute single-bout design, n=32 breast cancer survivors (16 RT, 16 HIIT), with serum myokine assay and in vitro MDA-MB-231 cell growth as surrogate co-primary outcomes; evidence level is low on the hierarchy for a clinical claim because the actual outcome measured is a laboratory surrogate, not a patient outcome.
Methodology & bias
Parallel-group acute RCT: 32 breast cancer survivors randomised to one bout of RT or HIIT, serum sampled at baseline, immediately post and 30 min post, with decorin/IL-6/SPARC/OSM measured by immunoassay and MDA-MB-231 (triple-negative) cell growth assessed by real-time impedance after serum exposure. Key risk-of-bias issues: no blinding of lab personnel to allocation reported, no power calculation or correction for multiple comparisons across four myokines and two time points, exercise protocols (load, intensity, duration) not detailed enough to replicate, and no control for diet, time of day, menstrual/menopausal status or baseline fitness that could confound myokine kinetics. The use of a single TNBC cell line further restricts generalisability of the "cancer cell suppression" finding to other receptor subtypes (ER+/HER2+) that make up the majority of survivors.
The appraisal
The myokine rises and in vitro cancer cell suppression are statistically significant (p<0.05) but this is a surrogate, mechanistic endpoint from a single acute exposure in 32 people; none of it has been linked to a patient-level outcome. A 19-29% reduction in MDA-MB-231 growth in a dish, using serum collected 0-30 min post-exercise, tells you exercise perturbs the circulating milieu acutely, not that recurrence risk changes, and the abstract's framing of "lower risk of recurrence" is not something this design can support.
The gap
There is no recurrence, survival or chronic-training outcome data, and a single acute bout cannot be assumed to mirror the myokine or immune profile produced by sustained training, so the paper's own conclusion about "lower risk of recurrence" outruns what the design can show.
Landmark context
This extends prior observational links between exercise, circulating myokines (IL-6, decorin, SPARC) and tumour biology into a controlled acute comparison of RT versus HIIT in breast cancer survivors, but it is hypothesis-generating mechanistic work, not a trial building on a named outcome-based landmark study.
What to do Monday
No change to Monday practice: this is acute mechanistic data from a 32-person trial with no recurrence, survival or chronic-training follow-up, so exercise prescription for survivors stays guided by established dosing guidelines and individual tolerance, not by this biomarker signal.
Apply this in practice
In the physio clinic, nothing here changes post-treatment exercise prescription: continue standard oncology-rehab dosing (progressive resistance 2x/week plus aerobic work building to 150 min/week moderate intensity) once oncology clearance, surgical healing and cardiotoxicity screening (echo/GLS if on anthracyclines or trastuzumab) are confirmed, and monitor fatigue, lymphoedema and bone health (DXA if on aromatase inhibitors) as usual ascertainment steps before loading. For the S&C coach, this paper is a rationale slide, not a programming tool: you cannot measure decorin, IL-6, SPARC or OSM in the gym, so RT-versus-HIIT selection should still be driven by patient preference, joint tolerance, treatment-related neuropathy or fatigue, and functional testing (grip strength, 30-second sit-to-stand, 6-minute walk) rather than by an assumed myokine spike. Both lenses should communicate the finding honestly to patients as "exercise does something biologically interesting and plausible" rather than implying a dose of HIIT today lowers their recurrence odds, since no recurrence or survival data exist to anchor that claim. Until a trial links a specific training modality, dose or duration to a hard oncology endpoint, individualised progressive loading with standard safety screening remains the only defensible Monday practice.
Appraise any paper on demand
This is one critical appraisal from Dose-Response. Join and appraise any sports-medicine, rehab or performance paper yourself — plus the five that matter, every week.
Join Dose-Response